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Abstract
Introduction: Breast cancer brain metastases (BCBM) are a challenging consequence of advanced BC. Nanoparticle agents,
including liposomes, have shown enhanced delivery to solid tumors and brain. We compared pharmacokinetics (PK) and
efficacy of PEGylated liposomal doxorubicin (PLD) with non-liposomal doxorubicin (NonL-doxo) in an intracranial model of
BC.
Methods: Athymic mice were inoculated intracerebrally with MDA-MB-231-BR-luciferase-expressing cells. Tumor-bearing
mice were administered PLD or NonL-doxo at 6mg/kg IV61 and were euthanized prior to and 0.083, 1, 3, 6, 24, 72 and 96 h
post-treatment. Samples were processed to measure sum total doxorubicin via HPLC. PLD and NonL-doxo were
administered IV weekly as single agents (6 mg/kg) or in combination (4.5 mg/kg) with the PARP inhibitor, ABT-888, PO
25 mg/kg/day. Efficacy was assessed by survival and bioluminescence.
Results: Treatment with PLD resulted in approximately 1,500-fold higher plasma and 20-fold higher intracranial tumor sum
total doxorubicin AUC compared with NonL-doxo. PLD was detected at 96 h; NonL-doxo was undetectable after 24 h in
plasma and tumor. Median survival of PLD-treated animals was 32 days (d, [CI] 31–38), which was significantly longer than
controls (26d [CI 25–28]; p = 0.0012) or NonL-doxo treatment (23.5d [CI 18–28], p = 0.0002). Combination treatment with
PLD/ABT-888 yielded improved survival compared to NonL-doxo/ABT-888 (35d [CI 31–38] versus 29.5d [CI 25–34]; p = 0.006).
Conclusions: PLD provides both PK and efficacy advantage over NonL-doxo in the treatment of an in vivo model of BCBM.
The results provide preclinical rationale to translate findings into early phase trials of PLD, with or without ABT-888, for
patients with BCBM.
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Introduction
Brain metastases arising from breast cancer are a burgeoning
clinical problem associated with decline in quality of life, loss of
independence, and poor survival [1]. The incidence of brain
metastases is highly subtype-dependent [2] such that patients with
triple negative and Her2-positive advanced breast cancer are at
highest risk for intracranial recurrence [3,4]. Moreover, prognosis
following the development of brain metastases is also associated
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with breast cancer subtype where survival following central
nervous system recurrence is 3 to 4 months for women with
triple-negative disease compared to 9 and 15 months for HER2-
positive and endocrine-sensitive counterparts, respectively [5]. The
current treatment paradigm for breast cancer brain metastases
(BCBM) across all subtypes includes radiation therapy (whole
brain and/or focused brain radiation) and/or surgical resection
[6]. Although studies illustrate systemic therapy sequenced after
cranial radiation improves outcome for many patients with breast
cancer brain metastases, the physical properties of the blood brain
barrier and the relative paucity of targeted agents to treat
intracranial breast cancer remains a significant challenge in the
development of systemic therapies capable of controlling both
intra- and extracranial advanced breast cancer [7,8,9].
The development of chemotherapeutic agents to effectively treat
solid tumors within or outside of the central nervous system
depends, in part, on the ability of these agents to achieve cytotoxic
drug exposure within the tumor(s). Encapsulating common anti-
cancer agents into nanoparticle delivery systems, particularly
liposomes, provides a promising approach to enhance central
nervous system delivery. Although the mechanism of enhanced
brain delivery is not completely understood, it is postulated that
the higher exposure to central nervous system tumors is related to
longevity in blood and altered distribution compared to non-
nanoparticle, standard, small molecule formulations [10,11,12].
Prolonged systemic exposure afforded by nanoparticle technology
may allow for permeation of tumor microcirculation via passive
convection transport through a blood brain barrier potentially
‘‘compromised’’ by the presence of tumor [10,11,12]. Chances for
extravasation improve with prolonged circulation half-life and a
greater number of circulation passages through a tumor bed.
Although factors inherent to intracranial tumor (i.e. increased
intracranial pressure) may dampen the effect of nanoparticle
transport into a tumor compartment, results of prior preclinical
and clinical studies argue that longer circulation time afforded by
nanoparticle formulations may overcome these effects [12,13,14].
However, the benefit of nanoparticle anti-cancer agents, with or
without targeted agents capable of crossing the blood brain
barrier, has yet to be fully examined in an in vivo model system of
intracranial breast cancer.
In the current study, we utilized an intracranial model of
aggressive triple negative breast cancer to evaluate the pharma-
cologic disposition and activity of a chemotherapeutic agent that is
highly active in the treatment of breast cancer, namely the
anthracycline doxorubicin [15], in a PEGylated liposome (PLD)
formulation as compared to non-liposomal doxorubicin (NonL-
doxo). To assess the efficacy of this approach, survival following
treatment with PLD was compared to treatment with NonL-doxo.
Finally, ABT-888, an inhibitor of a poly (ADP-ribose) polymerase
[PARP] and subsequent DNA repair, has been shown to cross the
blood brain barrier [16]. Thus, we sought to augment intracranial
efficacy by combining PLD, a DNA-damaging agent which
intercalates between base pairs of the DNA/RNA strand, thus
preventing macromolecular biosynthesis [17], with ABT-888 in an
intracranial model of breast cancer.
Materials and Methods
Ethics statement
All animal studies were conducted in accordance within the
guidelines of the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health and with the approval
of the University of North Carolina at Chapel Hill’s Institutional
Animal Care and Use Committee (IACUC) on protocols 09–151
and 10–230.
Cell lines and culture conditions
The MDA-MB-231-BR cell line was selected for study and was
kindly provided as a gift by Toshiyuki Yoneda, PhD (The
University of Texas Health Science Center of San Antonio)[18].
The MDA-MB-231-BR cell line and its parental cell line (MDA-
MB-231) were derived from a metastatic pleural effusion of a 51-
year old white female patient. The MDA-MB-231-BR cell line is a
‘brain-seeking’ subclone that, following serial in vivo and in vitro
selection, more frequently metastasizes to the brain in preclinical
models versus its parental line [18]. The MDA-MB-231-BR cell
line was cultured in DMEM (Life Technologies, Grand Island,
NY) with 10% FBS (fetal bovine serum; Sigma-Aldrich, St. Louis,
MO). The cell line was grown with penicillin/streptomycin (Life
Technologies, Grand Island, NY) at 37uC and 5% carbon dioxide.
Cells were harvested immediately prior to intracranial implanta-
tion. In addition, the identity of the MDA-MB-231-BR cell line
was confirmed by global gene expression analyses (September
2010).
Luciferase transduction of MDA-MB-231-BR
The MDA-MB-231-BR cell line was transduced with the
bicistronic lentiviral vector pTK1261 carrying the firefly Lucifer-
ase under the control of a CMV promoter and a fusion green
fluoresence protein/Blasticidin (PFG/BSD) under translational
control of an IRES. All lentiviral vectors were prepared by using
the calcium phosphate method to transiently transfect 293T cells
with 15 mg vector plasmid, 10 mg packaging plasmid, and 5 mg
envelope plasmid [19]. All vectors were pseudotyped with the
VSV-G envelope protein. Luciferase-expressing vector concentra-
tions were determined by p24gag ELISA.
Pharmacologic agents
Doxorubicin (NonL-doxo) and PEGylated liposomal doxorubi-
cin (PLD, DoxilH) were both obtained from the University of
North Carolina (UNC) Hospitals Pharmacy (Chapel Hill, NC).
The poly-ADP-ribose polymerase (PARP) inhibitor, ABT-888, was
synthesized by the Chemistry Center for Integrative Chemical
Biology and Drug Discovery at UNC (Dr. S. Frye). ABT-888 was
dissolved in PBS (phosphate-buffered saline, Life Technologies,
Grand Island, NY). The molecular weight of pure ABT-888 is
244.29 g/mol, while the molecular weight of the salt form (which
includes 2 HCl molecules) is 317.21 g/mol. All calculations were
performed using the molecular weight of the salt form of ABT-
888. The ability of ABT-888 to inhibit the formation of PAR was
confirmed by measuring PAR levels in MDA-MB-231-BR cellular
extracts using HT PARP in vivo Pharmacodynamic Assay II
(Trevigen, Gaitherburg, MD, data not shown).
Cell viability assay
A mitochondrial dye conversion assay (Cell Titer 96H Aqueous
One Solution Cell Proliferation Assay; Promega Corp., Madison,
WI) was used to measure cell viability after treatment. This assay
was conducted according to manufacturer’s instructions, with
modifications. Briefly, 10,000 MDA-MB-231-BR cells were seeded
in each well of a 96-well plate. Cell counting was performed with
an automated cell counter. Cells were allowed to adhere
overnight, and media was replaced with fresh media containing
a range of drug doses. After the specified treatment period, 20 ml
of tetrazolium compound inner salt (MTS) containing an electron
coupling reagent, phenazine ethosulfate (PES) was added in each
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well and incubated at 37uC for 1 hour (h). The MTS absorbance
was measured spectrophotometrically at 490 nm (minus back-
ground absorbance). All cytotoxic experiments were done in
triplicate.
Single agent and combination treatments in cell lines
The IC50, defined as the inhibitory concentration that caused a
50% reduction in MTS dye conversion (i.e. 50% in vitro response
inhibition), was defined for both ABT-888 and NonL-doxo after
72 h of treatment. Of note, PLD was not tested in vitro as the goal
of our study was to evaluate the differences in PK and efficacy of
PLD vs. NonL-doxo in an in vivo environment. Drug combination
interactions were analyzed using methods developed by Chou and
Talalay [20]. As per prior work [21], the following treatment
schedules were tested: 1) 72 hours (h) NonL-doxo followed by 72 h
ABT-888, 2) 72 h ABT-888 followed by 72 h NonL-doxo, and 3)
72 h concurrent schedule of NonL-doxo and ABT-888 in
combination. Using cell lines plated as described above, treatment
combinations consisting of a constant ratio of 308/1 (ABT888
[uM]/NonL-doxo [uM]) were applied to cells and growth was
measured compared to untreated controls using Cell Viability
assay.
Animal use and intracranial tumor inoculation
The mice were housed within a BSL2 facility and in sterile
caging. Therapeutic studies and assessment for response were
performed with the assistance of the Mouse Phase I Unit (MP1U).
Female, Foxn1nu/nu mice, approximately 20 grams and aged
8 weeks of age were bred in-house from animals purchased from
Charles River Laboratories International, Inc. (Wilmington, MA;
Stock #490) and were used for all studies. Prior to intracerebral
tumor inoculation, mice were anesthetized with ketamine 75 mg/
kg IP 61 and DomitorH 1mg/kg IP 61. Mice were placed into a
stereotactic frame (Kopf Model 900, Tujunga, CA) prior to
injection of 26105 MDA-MB-231-BR cells in a volume of 5uL of
5% methylcellulose and culture media. Cells were stereotactically-
injected into the right caudate nucleus of the basal ganglia using a
27 gauge needle (from Bregma a:1.0mm, l:-2.0 mm, d:-4.0 mm)
which remained in place for a period of 2 minutes (min) to
minimize reflux through the needle track.
Bioluminescence imaging
All animals were anesthetized via inhalation with 2% vaporized
isoflurane during the imaging process. Approximately 15 min
prior to imaging, all inoculated mice received an intraperitoneal
(IP) injection of D-Luciferin dissolved in PBS (150 mg/kg; Caliper
Life Sciences, Hopkinton, MA). To confirm the presence or
absence of intracranial tumor, mice were imaged using the IVIS
Lumina camera (Caliper Life Sciences, Hopkinton, MA). Images
were analyzed using Living Image 4.0 Software (Caliper Life
Sciences, Hopkinton, MA). All values were recorded as photons/
second and were corrected for the presence of background signal.
Pharmacokinetic study design
On Day 18 day following intracranial injections of 26105
MDA-MB-231-BR cells, mice were pair-matched into 2 treatment
groups. Intracranial tumor formation was confirmed by serial
bioluminescence imaging approximately 1 and 2 weeks post-
injection. Prior to treatment, the average luciferase signal
(photons/second) between groups was not statistically different
(data not shown). Group 1 (n = 23) received NonL-doxo admin-
istered over 10–15 seconds at 6 mg/kg IV 61 via tail vein. Group
2 (n = 23) received PLD administered over 10–15 seconds at 6
mg/kg (doxorubicin equivalents) IV 61 via tail vein.
Mice (n = 3 per time point, n = 2 prior to administration) were
sacrificed prior to administration, and at 0.083, 1, 3, 6, 24, 72 and
96 hours (h) after administration of NonL-doxo and PLD.
Approximately 1 mL of blood was collected via terminal cardiac
puncture following deep anesthesia (ketamine 100 mg/kg IP 61
and DomitorH 1 mg/kg IP 61) using sodium heparin as an
anticoagulant and centrifuged at 1,500 g for 5 minutes to collect
plasma. Brain tumor, peri-tumoral brain and normal (contralat-
eral, non-tumor) brain were collected from each mouse. Plasma,
tumor, and tissues were placed in cryopreservation vials and
preserved by snap freezing using liquid nitrogen. All samples were
stored at 280uC until analysis.
Sample processing and analytical method
Total tissue and tumor weight was recorded at time of
collection. Whole tissue and tumors were snap frozen in liquid
nitrogen and stored at 280uC until homogenized. To form tissue
and tumor homogenates, the intact tissues and tumors were
thawed and sectioned [11]. The sections were weighed and diluted
in a 1:3 ratio with phosphate buffered saline (PBS) solution.
Finally, these mixtures were homogenized by placing zirconium
oxide beads (15 small and 2 large; Omni International Inc,
Kennesaw, GA) into 2 mL tubes at 3,0006g using a Precellys 24
homogenizer (Omni International Inc, Kennesaw, GA) twice for
15 sec each with a 5 sec wait between each run.
Samples were further processed for the analytical studies using
protein precipitation with acetonitrile. An 800 mL of extraction
solution containing internal standard (acetonitrile with 100 ng/mL
daunorubicin) was added to 200 mL of plasma, tumor or tissue
homogenate into a 2 mL microcentrifuge tube. The samples were
vortexed for 10 min and centrifuged at 10,0006g for 10 min at
4uC. A 900 mL of the supernatant was decanted into clean tubes,
evaporated under nitrogen in TurboVap and reconstituted in
150 mL of 25% acetonitrile solution (containing 0.026 M
Na2HPO4, 3.5 mM triethylamine and pH adjusted to 4.6 with
3M citric acid). The samples were then vortexed, transferred into
auto-sampler vials and analyzed by high-performance liquid
chromatography (HPLC) using fluorescence (FL) detection (exci-
tation wavelength: 490 nm/ emission wavelength: 590 nm). The
HPLC-FL method to measure sum total (encapsulated and
released) doxorubicin in plasma, tumor, and tissues was modified
from previous studies [22,23,24].
Efficacy study design
Mice with luciferase-confirmed intracranial tumor were placed
into the following treatment groups 7 to 14 days following
intracranial inoculation of MDA-MB-231-BR cells: 1) control,
IV (via tail vein) PBS (100 uL) weekly, 2) NonL-doxo 6 mg/kg IV
weekly, (3) PLD 6 mg/kg IV weekly, (4) ABT-888 25 mg/kg/day
via oral gavage (OG), (5) NonL-doxo 4.5 mg/kg IV weekly plus
ABT-888 OG 25 mg/kg/day, or (6) PLD 4.5 mg/kg IV weekly
plus ABT-888 OG 25 mg/kg/day. Treatment was ongoing until
clinical symptoms necessitated sacrifice. Prior to treatment, the
average luciferase signal (photons/second) between groups and
within each experiment was not statistically different (data not
shown). Mice were weighed a minimum of three times/weekly and
were monitored by optical imaging weekly until clinical symptoms
(i.e. decreased response to stimuli, neurologic dysfunction, weight
loss of 20% and/or a Body Composition Score of 2 or less)
necessitated sacrifice.
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Statistical analysis
Cell line studies. CalcuSyn (BioSoft, Cambridge, UK) was
used to estimate the IC50 for each drug and to determine the
combination index, which is a measurement of the type of drug
interactions. A combination index (CI) of 1 indicates an additive
response, ,1 indicates a synergistic response, and .1 indicates an
antagonistic response.
Pharmacokinetic analysis. The pharmacokinetics of PLD
and NonL-doxo in plasma, tumor and tissues were analyzed by
noncompartmental analysis using WinNonlin Professional Edition
version 5.2.1 (Pharsight Corp., Cary, NC). The area under the
concentration versus time curve from 0 to ‘ (AUC0–‘) was
calculated using the linear up/log down rule. The plasma volume
of distribution (Vd), clearance (CL), and half-life (t1/2) were
calculated using standard equations. The maximum concentration
(Cmax) and time of Cmax (tmax) were determined by visual
inspection of the concentration versus time data.
Efficacy analysis. The Kaplan-Meier method and Log-rank
tests were used to evaluate and compare overall survival among
treatment groups. Unadjusted p-values are reported. For biolu-
minescence imaging, fold changes were calculated relative to the
start date of treatment. If present, negative imaging values (due to
correction for background) were recorded and set to zero. For
every time point where at least two animals were alive in the
treatment group, the median level and interquartile range (25th–
75th percentile) for bioluminescence imaging were calculated.
Results
Pharmacologic disposition and drug efficacy studies were
conducted in a murine model of intracranial breast cancer.
Briefly, 26105 MDA-MB-231-BR cells were stereotactically
implanted into the right caudate nucleus of Foxn1nu/nu mice.
Intracranial tumor formation was monitored in vivo via biolumi-
nescence imaging (mean signal 4.56106, standard deviation
7.06106 photons/second approximately 7 days post-implanta-
tion). Liposomal and non-liposomal drugs were administered, and
tumor and body tissue drug concentrations determined over time.
The median survival of treated versus untreated animals (26 days,
95% Confidence Interval [CI] 25–28 days) was determined as an
objective measure of efficacy.
Pharmacokinetic study results: plasma, tissue and tumor
pharmacokinetic disposition
Nonliposomal Doxorubicin (NonL-doxo). The concentra-
tion versus time profile of sum total doxorubicin in plasma, brain
tumor, peri-tumoral, and contralateral non-tumor brain after
administration of NonL-doxo is presented in Figure 1. The
pharmacokinetic parameters after administration of NonL-doxo
are presented in Table 1. After administration of NonL-doxo, the
plasma concentration versus time profile of sum total doxorubicin
peaked at 0.083 h (5 min) after administration, and had a bi-
phasic elimination profile as previously reported [12]. After
administration of NonL-doxo, sum total doxorubicin concentra-
tions were undetectable after 3 h in normal (contralateral, non-
tumor) brain, 6 h in peri-tumoral brain, and 24 h in plasma and
brain tumor. The exposure of sum total doxorubicin was higher in
brain tumor compared to normal and peri-tumoral brain from 1 to
24 h.
PEGylated liposomal-doxorubicin (PLD). The concentra-
tion versus time profile of sum total doxorubicin in plasma, brain
tumor, peri-tumoral brain and contralateral non-tumor brain after
administration of PLD is presented in Figure 2. The pharma-
cokinetic parameters after administration of PLD are presented in
Table 1. After administration of PLD, the plasma concentration
versus time profile of sum total doxorubicin had a bi-phasic
elimination profile, and was detectable until 96 h after adminis-
tration. The long circulation of PLD in plasma was consistent with
previous studies [25]. The concentration versus time profiles of
sum total doxorubicin after administration of PLD in normal
(contralateral, non-tumor) and peri-tumoral brain were similar to
the profile in plasma; however, sum total doxorubicin concentra-
tion was undetectable in normal brain after 72 h. The exposure of
sum total doxorubicin in tumor was higher than normal and peri-
tumoral brain and was maintained until 96 h.
The plasma exposure for sum total doxorubicin as measured by
the AUC was approximately 1,500-fold higher after administra-
tion of PLD as compared with NonL-doxo. CL and Vd of sum
total doxorubicin after administration of PLD (CL: 2.65 mL/h/kg,
Vd: 113.5 mL/kg, t1/2: 30 hours) were much lower as compared
to those of NonL-doxo (CL: 3,882.7 mL/h/kg, Vd: 56,238 mL/
kg, t1/2: 10 hours), indicating prolonged circulation and higher
plasma exposures for PLD compared with NonL-doxo. The AUC
of sum total doxorubicin after administration of PLD was
approximately 20-fold higher in brain tumor, 42-fold higher in
normal (contralateral non-tumor) brain, and 84-fold higher in
peri-tumoral brain as compared with NonL-doxo, indicating
greater delivery of sum total doxorubicin to brain tumor and
brain.
Single-agent efficacy results
The therapeutic effect of NonL-doxo versus PLD was assessed
in an intracranial model of breast cancer 7 to 14 days after
stereotactic implantation of the MDA-MB-231-BR cells. Animals
received weekly IV tail vein injections of either PBS control
(100uL), NonL-doxo (6 mg/kg) or PLD (6mg/kg) until clinical
symptoms necessitated sacrifice. The results are the product of 3
independent experiments across which there were no significant
difference in the survival of control group animals (data not shown,
[medians of 27 (CI = 24–31), 26 (CI = 18–28), 24 (CI = 18–29),
p = 0.24]. The median survival of the control and NonL-doxo
treated groups was not statistically different [p = 0.26; medians of
26 (CI = 25–28) and 23.5 days (CI 18–28), respectively; Table 2;
Figure 3A]. In contrast, the median survival of PLD treated
animals was 32 days (CI, 31–38) which was significantly longer
than control (p = 0.0012) and NL- doxo (p = 0.0002) treated
groups.
PARP inhibitor combinations
Combination studies. To further augment therapeutic
efficacy in the intracranial model of breast cancer, combination
anthracycline-based therapy with the PARP inhibitor, ABT-888,
was investigated. In vitro single agent and combination studies
utilizing the MDA-MB-231-BR cell line were performed. As single
agents, the IC50 doses of NonL-doxo and ABT-888 for the MDA-
MB-231-BR cell line were 242 nM and 277 mM at 72 hours,
respectively.
To determine if the combination of NonL-doxo and ABT-888
was additive, synergistic or antagonistic, MDA-MB-231-BR cells
were treated with three schedules: 1) 72 hours NonL-doxo
followed by 72 hours of ABT-888, 2) 72 hours ABT-888 followed
by 72 hours NonL-doxo, and 3) a 72 hours of NonL-doxo and
ABT-888 in combination. As shown in Figure 4A, treatment with
NonL-doxo plus ABT-888 in combination for 72 hours showed
similar results in terms of cell death compared to 72 h of ABT-888
prior to 72 h of NonL-doxo. However, sequencing NonL-doxo
prior to ABT-888 resulted in enhanced cell death. Concordant
with IC50 results and our hypothesis that DNA damage prior to
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inhibition of DNA repair would prove most effective, we observed
that treatment with NonL-doxo for 72 h followed by ABT-888 for
72 h was synergistic at most doses (Figure 4B). Both combination
treatment and sequential treatment with ABT-888 prior to NonL-
doxo showed additivity and antagonism at most doses, with
synergy at or above IC50 dosing.
In addition and in preparation for in vivo combination efficacy
studies, a pilot toxicity study of NonL-doxo and ABT-888 was
performed in 6 tumor-free FVB/NJ females aged 6 to 8 weeks
(Jackson Laboratory, Stock #001800). Two mice were evaluated
at each dose level of NonL-doxo: 6 mg/kg, 4.5 mg/kg, and 3 mg/
kg (intraperitoneal) IP weekly63 weeks in combination with ABT-
888 oral gavage (OG) 25 mg/kg/day. Treatment was adminis-
tered for 21 days during which body mass and body composition
score (BCS) were observed for a total of 49 days. Drug toxicity was
noted in a dose-dependent manner. NonL-doxo 6mg/kg IP weekly
with ABT-888 OG 25 mg/kg/day, was associated with early
decline (both animals sacrificed at 30 days). NonL-doxo 4.5 mg/
kg IP weekly in combination with ABT-888 OG 25 mg/kg/day
resulted in one sacrifice (42 days); no other adverse effects were
noted within the cohort. No adverse events were observed in the
3 mg/kg NonL-doxo plus ABT-888 mice throughout the study.
Based on pilot dosing, historical data [16,26], and the investiga-
tors’ experience with PLD dosing, 4.5 mg/kg IV weekly for both
NonL-doxo and PLD combined with ABT-888 25 mg/kg OG
was selected as the maximum tolerated dose for further study.
Survival. Combination therapy of PLD with ABT-888
resulted in improved median overall survival (35 day, CI 31–38)
as compared to control-treated (p,0.0001) and NonL-doxo plus
ABT-888-treated animals (29.5 days, CI 25–34; p = 0.006; see
Table 2 and Figure 3B). Interestingly, the addition of ABT-888
to PLD only minimally improved the survival of animals treated
with PLD alone (35 days, CI 31–38 versus 32 days, CI 31–
38 days, respectively; p = 0.3; data not shown). Both therapies,
PLD alone or with ABT-888 were superior to control-treated
animals (p = 0.0012 and p,0.0001, respectively). Finally, and for
Figure 1. Sum Total Doxorubicin Concentrations from NonL-doxo. Individual and mean sum total doxorubicin concentration in plasma,
brain tumor, contralateral non-tumor brain, and peri-tumoral brain of female athymic nude (nu/nu) mice bearing intracranial MDA-MB-231-BR human
triple-negative breast cancer xenografts following administration of nonliposomal doxorubicin (NonL-doxo) at 6 mg/kg IV61. Samples (n = 3 mice at
each time point) were obtained at 0.083, 1, 3, 6, 24, 72 and 96 hours following administration of NonL-doxo. Concentrations were undetectable after
3 hours (contralateral non-tumor brain), 6 hours (peri-tumoral brain), and 24 hours (plasma and tumor) of administration. (A) 0–96 h; (B) 0–6 h.
doi:10.1371/journal.pone.0061359.g001
Table 1. Pharmcokinetic parameters for PLD and NonL-doxo.
Matrix Pharmacokinetic Parameters
PEGylated liposomal-doxorubicin Non-liposomal doxorubicin
AUC0-(ng/mL?h) tmax(h) Cmax(ng/mL) AUC0-‘(ng/mL?h) tmax(h) Cmax(ng/mL)
Plasma 2,257,480 3 197,020 1,545 0.083 831
Brain Tumor 229,716 3 2,181 12,134 6 570
Normal Brain 13,742 3 854 326 1 92
Peri-Tumoral Brain 23,972 3 725 283 3 32
Noncompartmental pharmacokinetic parameters following administration of PEGylated liposomal-doxorubicin and non-liposomal doxorubicin at 6 mg/kg IV 61 in
female athymic nude (nu/nu) mice bearing intracranial MDA-MB-231-BR human triple-negative breast cancer xenografts.
doi:10.1371/journal.pone.0061359.t001
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completeness, single agent therapy with ABT-888 was compared
to control with no differences observed (27 days, [CI 24–31] and
26 days [CI 25–28], p = 0.5; data not shown).
Bioluminescence studies. In addition to overall survival,
dynamic change (fold change from start of treatment as measured
in photons/second) in the signal intensity of intracranial tumors
was evaluated by bioluminescence imaging to assess efficacy of
individual and combination therapeutics (Figure 5A and 5B). As
expected, the highest fold change from baseline in biolumines-
cence was observed in control-treated animals (median 87.8,
Interquartile range [IQR] 38.5–88.5, 3 weeks post-treatment)
followed by ABT-888-treated animals (median 41.8, IQR 0.03–
63.2, 4 weeks post-treatment). The highest median fold-change in
animals treated with either NonL-doxo or PLD as single agents
was 4.6 (IQR 3.36–5.90, 3 weeks post-treatment) and 3.4 (IQR
0.79–4.37, 6 weeks post-treatment), respectively. Interestingly,
among animals treated with combination NonL-doxo plus ABT-
888 and PLD plus ABT-888, a peak in bioluminescence fold-
Figure 2. Sum Total Doxorubicin Concentrations from PLD. Individual and mean sum total doxorubicin concentration in plasma, brain tumor,
contralateral non-tumor brain, and peri-tumoral brain of female athymic nude (nu/nu) mice bearing intracranial MDA-MB-231-BR human triple-
negative breast cancer xenografts following administration of PEGylated liposomal-doxorubicin (PLD) at 6 mg/kg IV 61. Samples (n = 3 mice at each
time point) were obtained at 0.083, 1, 3, 6, 24, 72, and 96 hours following administration of PLD. (A) 0–96 h; (B) 0–6 h.
doi:10.1371/journal.pone.0061359.g002
Figure 3. Efficacy Studies in an intracranial model of breast cancer. (A) Median survival (from the time of intracranial cell line injection) of
animals treated with control (PBS, black), non-liposomal doxorubicin (NonL-doxo, green) 6mg/kg IV weekly and PEGylated liposomal doxorubicin
(PLD, blue) 6mg/kg IV weekly in a murine model of intracranial breast cancer. (B) Median survival of animals treated with control (PBS, black), NonL-
doxo 4.5 mg/mg IV weekly plus ABT-888 25 mg/kg OG daily (yellow) versus PLD (red) 4.5mg/mg IV weekly plus ABT-888 25 mg/kg OG daily in a
murine model of intracranial breast cancer.
doi:10.1371/journal.pone.0061359.g003
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change was noted early (median 3.67, IQR 1.58–7.04 and 5.42
IQR 2.01–11.95, respectively, 2 weeks post-treatment), followed
by a decline in signal over time. At 5 weeks post-treatment,
median bioluminescence fold-change was 0.10 (IQR 0.01–0.19)
for NonL-doxo plus ABT-888-treated animals. Finally, 10 weeks
post-treatment, median bioluminescence fold-change was 0.00
(IQR 0.00–0.00) for PLD plus ABT-888 animals.
Discussion
As systemic therapies for breast cancer improve, the develop-
ment of breast cancer brain metastases has emerged as a
significant challenge in the management of patients with advanced
breast cancer [1]. While the blood brain barrier is often
compromised by the presence of intracranial tumor, it remains
an impediment to systemic delivery of promising systemic
therapies, including anthracyclines [27]. We report here, in a
murine model of intracranial breast cancer, that PLD results in
higher and prolonged plasma and intracranial tumor exposure as
compared to NonL-doxo. Specifically, the sum total plasma
AUC0–‘ of PLD was 1,500 times higher than that of NonL-doxo.
Moreover, PLD was detected at 96 hours in plasma illustrating
prolonged exposure as compared to NonL-doxo (undetectable
after 24 hours). The plasma pharmacokinetic results of PLD and
NonL-doxo are consistent with prior studies [10,12,13,14,28].
With regard to intracranial tumor, there were higher sum total
doxorubicin concentrations after administration of PLD compared
to NonL-doxo. Importantly, intracranial tumor sum total doxo-
rubicin concentrations remained elevated at 96 hours, whereas the
concentrations of doxorubicin after administration of NonL-doxo
were non-detectable in brain and brain tumors after 24 hours.
In parallel to improved pharmacologic disposition, we report
improved survival after administration of PLD as compared to
control and NonL-doxo treatment in this MDA-MB-231-BR
model of intracranial breast cancer. In contrast to our in vitro
results, the addition of a small molecule PARP inhibitor capable of
crossing the blood brain barrier, ABT-888[16], to PLD did not
significantly improve survival as compared to single agent PLD.
Interestingly, combination therapy with ABT-888 and PLD
resulted in significant improvements in survival when compared
to NonL-doxo plus ABT-888. In light of prior work illustrating
similar efficacy and an improved toxicity profile (i.e. improved
cardiac toxicity) for PLD as compared to NonL-doxo in patients
with extracranial advanced breast cancer [29], our results provide
sound preclinical rationale to support the design of clinical trials
Table 2. Median survival of intracranial breast cancer model.
Treatment Groups Dose(mg/kg) Mice per group
Median Survival and 95%
CI(days) P value (compared to control)*
Control (PBS) N/A 33 26 (25 – 28) N/A
NonL-doxo 6mg/kg IV 20 23.5 (18 – 28) 0.26
PLD 6mg/kg IV 20 32 (31 – 38) 0.0012
ABT-888 25m/kg OG 18 27 (24 – 31) 0.5
NonL-doxo plus ABT-888 4.5mg/kg IV and 25mg/kg OG 36 29.5 (25 – 34) 0.04
PLD plus ABT-888 4.5mg/kg IV and 25mg/kg OG 35 35 (31 – 38) , 0.0001
Median Survival of an intracranial breast cancer model treated with Control (PBS), non-liposomal doxorubicin (NonL-doxo) versus PEGylated Liposomal Doxorubicin
(PLD).
*P value for NonL-doxo vs. PLD = 0.0002; p value for NonL-doxo/ABT-888 vs. PLD/ABT-888 = 0.006.
Abbreviations: IV, intravenous; OG, oral gavage.
doi:10.1371/journal.pone.0061359.t002
Figure 4. Sequential and combination treatment of the MDA-MB-231-BR cell line with ABT-888 and non-liposomal doxorubicin
(NonL-doxo). (A) Percentage of viable cells treated in each of three treatment arms (72 hours [h] ABT-888 followed by 72 h NonL-doxo [blue], 72 h
NonL-doxo followed by 72 h ABT-888 [red], and 72 h concurrent schedule of NonL-doxo and ABT-888 in combination [green]). (B) Combination index
(CI) analysis in each arm compared to treatment with single agents. Note: CI ,0.1–0.9, synergy; CI 0.9–1.1, additivity; CI .1.1, antagonism.
doi:10.1371/journal.pone.0061359.g004
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evaluating PLD with or without the PARP inhibitor, ABT-888, to
treat patients with breast cancer brain metastases – particularly
those with triple negative disease whose disease often presents both
intra- and extracranially and for whom targeted systemic therapies
are few [4]. However, while our results also support the study of
other nanoparticle anticancer agents in the treatment of primary
and metastatic intracranial tumors, we cannot recommend
translation of our work to PLD with other PARP inhibitors, other
than ABT-888, as the efficacy results of doxorubicin in combina-
tion with PARP inhibitors, (i.e. AG014699, INO-1001) have been
mixed [30,31].
The pharmacokinetics of nanoparticle drugs, e.g. PLD, is
dependent upon the carrier and not the encapsulated drug until
the drug is released from the carrier [32,33,34]. The drug that
remains encapsulated within liposomes or nanoparticles is an
inactive prodrug, thus the drug must be released from the carrier
to be active (active warhead). Nanoparticles and liposomes are
cleared via the mononuclear phagocyte system (MPS), which is
located primarily in the liver and spleen, as well as in the lung,
bone marrow and blood [28,35,36,37]. Nanoparticles and
liposomes can alter both the tissue distribution and the clearance
of drugs because the drug takes on the PK characteristics of the
carrier [10,33,34]. The ability of nanoparticle agents to deliver
drug to brain/brain tumors has not been extensively evaluated.
However, our study suggests that PLD achieved approximately 20-
fold higher exposures of drug into the brain tumors than the
NonL-doxo. Moreover, the results of this study can have a far
reaching impact as there are .300 nanoparticle anticancer agents
containing various anticancer agents as cargo in preclinical and
clinical development that may have enhanced delivery to
intracranial tumors, which may results in greater efficacy for the
treatment of CNS-located epithelial malignancies [33,34,38].
Prior studies also suggest that nanoparticle agents can deliver
more drug to brain than their non-nanoparticle counterparts.
Walsh et al [11] showed that XMT-1001, a macromolecular
camptothecin (CPT) conjugate, administered at 60mg CPT
equivalents/kg in mice bearing HT-29 human colon carcinoma
xenografts delivered 5-fold higher exposures of camptothecin into
brain than irinotecan (administered at 100 mg/kg CPT equiva-
lents). In a study comparing the plasma, tumor, and tissue
pharmacokinetics of PEGylated liposomal CKD-602 (S-CKD602)
and nonliposomal CKD-602 (a camptothecin analog) in mice
bearing A-375 human melanoma xenografts, S-CKD602 deliv-
ered approximately 3-fold higher exposures of the CKD-602 into
brain as compared to non-liposomal CKD-602 [10] after
administration of only 1/30th of the dose of non-liposomal
CKD-602. Siegal et al. showed that PLD achieved 15-fold higher
doxorubicin levels in brain tumors of fisher rats after 48 hours of
administration as compared to NonL-doxo [12].
Although the mechanism of enhanced CNS delivery of
nanoparticles is not completely understood, it is postulated that
higher exposure to CNS tumors is related to nanoparticle
longevity in circulation compared to non-nanoparticle formula-
tions. Penetration of small molecule anti-cancer agents across the
Figure 5. Bioluminescence imaging of TNBC intracranial tumor model. (A) Dynamic changes in intracranial tumor growth after treatment as
measured by bioluminescence imaging in photons/second. Groups are as follows: Control (black), non-liposomal doxorubicin (NonL-doxo, green),
PEGylated liposomal doxorubicin [PLD] (blue), ABT-888 (purple), NonL-doxo/ABT-888 (yellow) and PLD/ABT-888 (red). The median fold changes are
connected over time for each treatment group. The vertical bars indicate the interquartile rages (25th–75th percentiles). Points are only plotted when
there were at least 2 animals in a treatment group. (B) Representative images of intracranial bioluminescence by treatment group 14 days post-
treatment initiation.
doi:10.1371/journal.pone.0061359.g005
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blood brain barrier is limited by molecular weight, polarity, efflux
mechanisms (i.e. P-glycoprotein), and short half-life [8,9]. We
hypothesize that prolonged systemic exposure afforded by
nanoparticle technology allows for permeation of tumor micro-
circulation via passive convection transport through a BBB
potentially ‘‘compromised’’ by the presence of tumor. Chances
for extravasation improve with prolonged circulation half-life and
a greater number of circulation passages through a tumor bed.
Although factors inherent to intracranial tumor (i.e. lack of
lymphatic drainage, increased intracranial pressure) may dampen
the effect of nanoparticle transport into a tumor compartment,
results of preclinical and clinical studies argue that longer
circulation time afforded by nanoparticle formulations abrogate
these effects [12,13,14]. Moreover, several investigators have
sought to augment nanoparticle delivery to the CNS via strategic
targeting of liposomes to receptors selectively expressed by cell
lines and human tumors. As an example, treatment with
doxorubicin encapsulated in interleukin-13 (IL-13)-conjugated
liposomes resulted in improved survival and enhanced tumor
reduction in an intracranial model of glioblastoma multiforme
(GBM) as compared to unconjugated liposomes with the same
doxorubicin concentration [39]. More specific to breast cancer, a
second study has shown that PLD targeting integrin a5b1, over-
expressed in tumor vasculature and cancer cells, results in higher
cytotoxicity when treating MDA-MB-231 a5b1-expressing, breast
cancer cell lines than non-targeted liposomes [40]. Future studies
of targeted liposomes to treat intracranial breast cancer are
warranted.
We recognize that our study has several limitations. First, the
murine model selected to perform both the pharmacokinetic and
efficacy studies of PLD versus NonL-doxo is an intracranial model
of breast cancer per direct intracranial implantation. The goal of
this project; however, was to treat established intracranial tumor to
test intracranial drug delivery and efficacy as opposed to
prevention of colonization of the central nervous system pharma-
cologically (i.e. tumor growth inhibition) in which models of brain
metastases arising from hematogenous injection are routinely used
[27]. Moreover, an intracranial approach has historically been
employed as an accepted model to study both secondary and
primary brain tumors [12,41]. We view our data as a ‘‘proof of
concept’’ such that other pharmacologic agents (both chemother-
apeutics and targeted agents) may be more efficiently delivered to
the central nervous system using similar technology.
Conclusions
In conclusion, results of this study indicate that the pharmaco-
logic and efficacy profile of PLD is superior to that of NonL-doxo
in an intracranial model of established breast cancer brain
metastases. Moreover, the addition of the PARP inhibitor, ABT-
888, to PLD resulted in improved survival as compared to NonL-
doxo plus ABT-888 in this model. Taken together, our results
represent a novel and efficacious strategy in a preclinical setting –
liposomal delivery of a chemotherapeutic alone or in combination
with a small molecule PARP inhibitor – to treat breast cancer
brain metastases. These results provide strong rationale to
translate our findings into early phase trials evaluating PLD, with
or without ABT-888, among patients with breast cancer brain
metastases, including those with triple negative disease, with the
goal of improving outcome for patients with such a devastating
disease.
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